FDA removes partial clinical hold on MacroGenics' Phase 2 LINNET study of lorigerlimab

MACROGENICS INC

FDA lifted partial clinical hold on Phase 2 LINNET study of lorigerlimab (bispecific DART targeting PD-1 and CTLA-4).
Revised protocol includes additional risk-mitigation measures for potential hematologic and cardiac toxicities.
MacroGenics plans to resume enrollment in gynecologic cancers (PROC and CCGC); 41 patients dosed to date.
Existing participants continued receiving study drug during the hold; over 300 dosed across all lorigerlimab studies.
Company remains on track to provide a mid-2026 clinical update on the program.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.